Universal Beteiligungs und Servicegesellschaft mbH Increases Stake in STERIS plc $STE

Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in STERIS plc (NYSE:STE) by 13.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 57,218 shares of the medical equipment provider’s stock after purchasing an additional 6,613 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.06% of STERIS worth $14,158,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the stock. Chicago Partners Investment Group LLC acquired a new stake in shares of STERIS during the 3rd quarter worth $424,000. Jackson Thornton Wealth Management LLC purchased a new stake in STERIS during the third quarter valued at about $480,000. Root Financial Partners LLC purchased a new stake in STERIS during the third quarter valued at about $39,000. QTR Family Wealth LLC acquired a new stake in STERIS during the third quarter worth about $234,000. Finally, Allstate Corp purchased a new position in shares of STERIS in the 3rd quarter worth about $879,000. Hedge funds and other institutional investors own 94.69% of the company’s stock.

STERIS Price Performance

STE stock opened at $259.44 on Friday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.63 and a current ratio of 2.37. STERIS plc has a 1 year low of $204.90 and a 1 year high of $269.44. The firm has a market cap of $25.46 billion, a P/E ratio of 37.28 and a beta of 1.03. The stock has a 50-day simple moving average of $258.84 and a 200-day simple moving average of $247.46.

STERIS (NYSE:STE) last released its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $2.47 EPS for the quarter, topping the consensus estimate of $2.38 by $0.09. The firm had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.43 billion. STERIS had a return on equity of 14.43% and a net margin of 12.07%.During the same period in the previous year, the company posted $2.14 EPS. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. On average, equities analysts predict that STERIS plc will post 9.08 earnings per share for the current fiscal year.

STERIS Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, December 18th. Stockholders of record on Tuesday, November 18th were paid a $0.63 dividend. The ex-dividend date was Tuesday, November 18th. This represents a $2.52 annualized dividend and a dividend yield of 1.0%. STERIS’s dividend payout ratio is 36.21%.

Insider Activity at STERIS

In related news, VP John Adam Zangerle sold 15,000 shares of STERIS stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $265.14, for a total transaction of $3,977,100.00. Following the sale, the vice president owned 33,669 shares of the company’s stock, valued at $8,926,998.66. The trade was a 30.82% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Julia Madsen sold 5,008 shares of the business’s stock in a transaction on Friday, November 21st. The stock was sold at an average price of $262.00, for a total transaction of $1,312,096.00. Following the completion of the transaction, the vice president owned 10,710 shares in the company, valued at $2,806,020. This represents a 31.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 25,044 shares of company stock valued at $6,586,218. Corporate insiders own 1.07% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “buy (b)” rating on shares of STERIS in a report on Friday, January 9th. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, STERIS presently has a consensus rating of “Moderate Buy” and a consensus target price of $273.50.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.